Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
N Engl J Med 392(5):427437 Pratley RE, Tuttle KR, Rossing P, Rasmussen S, Perkovic V, Nielsen OW et al (2024) Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial
Regarding the commencement of its INSPIRE (International SCENESSE Pilot Repigmentation Evaluation) program to evaluate the use of its first-in-class drug SCENESSE (afamelanotide) as a repigmentation therapy in vitiligo, Dr Mark Lebwohl, Professor and Chair of Dermatology at Mount Sinai Hospital in New York and an investigator on the Clinuvel study, said: I think this is an exciting, major advancement for vitiligo, a disease for which we do not have adequate effective treatments,
A prolonged period of observation and treatment for these symptoms may be necessary, taking into account the long half-life of RYBELSUS of approximately 1 week
For larger volumes (50+ units), dead space is negligible
